Preclinical evidence supports this approach, demonstrating synergy between E2F inhibition and PD-1 blockade in MYC-driven tumors (17), suggesting that our E2F-immune classifier could guide personalized immunotherapeutic strategies in NB beyond conventional risk stratification. This evidence concerns the gene MYC and neuroblastoma.